Can Covid denialism get you elected? How is the music business like biotech investing? And what’s at stake for science in the midterms?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Sarah Owermohle joins us to discuss how pandemic shutdowns, Covid-19 vaccines, and the prospect of arresting Anthony Fauci have become campaign rallying cries in midterm elections. We also discuss the latest news in the life sciences, including the potential effects of federal drug-price negotiation and the virtues of befriending Pharrell Williams.
As biopharma moves past the pandemic, overcoming industry challenges remains a top priority
Covid-19 has pushed biopharma to embrace innovations that are creating the next wave of lifesaving diagnostics, vaccines, and therapies. Based on a recent survey of industry leaders, Cytiva’s Global Biopharma Resilience Index helps shed light on both the exciting future that lies ahead for medicine as well as the ongoing challenges that have to be addressed along the way, such as sourcing talent, collaborating with regulatory bodies, and ensuring a robust supply chain. Here’s what biopharma executives and healthcare policy makers told us about what to expect next.
No comments